55 results about "Mitiromycin" patented technology

The invention belongs to the technical field of microbes and specifically relates to Stenotrophomonas maltophilia and wide-spectrum maltocin synthesized from Stenotrophomonas maltophilia and application thereof. The Stenotrophomonas maltophilia is named Stenotrophomonas maltophilia S16 strain and was preserved in the China Center for Type Culture Collection with the preservation number being CCTCCM 2017431. The Stenotrophomonas maltophilia S16 strain is a new strain, and the strain can be induced by mitomycin C to produce maltocin S16. The maltocin S16 has high bactericidal activity and widebactericidal spectrum, can kill most Stenotrophomonas maltophilia as well as Escherichia coli, has resistance to protease, is relatively stable at high temperature, and has a good development and application prospect.

A multilocular liposome of mitomycin for preventing and treating tumor is prepared through dissolving the lipoid component (neutral phosphatide, cholesterol and neutral lipid) in organic solvent, dissolving mitomycin in buffering salt solution, mixing, emulsifying to obtain water-in-oil primary emulsion, adding external water phase containing isotonic regulator, stirring to become water-in-oil-in-water emulsion, and removing organic solvent.

The present invention features monoclonal antibodies LA1 or LA22 conjugated with mitomycin C, pingyangmycin or other anti-cellular agents. The present invention also features other anti-EGFR antibodies conjugated with mitomycin C or pingyangmycin. The antibodies of the present invention can be used to treat cancers, including but not limited to, those of epithelial origin, such as glioblastoma or cancer of the lung, breast, head and neck, and bladder.

Disclosed is a slow release injection agent of anticancer composition containing platinum-group compounds and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the platinum-group compounds are selected from cisplatin, Carboplatin, Nedaplatin or Oxaliplatin, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or Temozolomide, and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.

The invention discloses a preparation method of feeder cells for rapid culture of tumor infiltrating lymphocytes. The preparation method comprises the steps that peripheral blood lymphocytes are treated by using mitomycin C to obtain the feeder cells, and then the feeder cells and pre-cultured tumor infiltrating lymphocytes are co-cultured. The efficiency of expanding the tumor infiltrating lymphocytes of the feeder cells produced by the preparation method is better than that of the feeder cells produced by gamma-ray irradiation, and meanwhile the cost of using the preparation method is significantly lowered. The preparation method is simple and easy to operate, and can be widely applied and promoted.

The invention relates to the field of medicines, in particular to a phosphorothioate modified nucleic acid aptamer medicine conjugate as well as a preparation method and an application thereof. The phosphorothioate modified nucleic acid aptamer drug conjugate comprises a drug molecule group and a phosphorus-sulfur bond substituted nucleic acid aptamer fragment, wherein the drug molecule group is selected from a mitomycin C group, and the drug molecule group is connected with the phosphorus-sulfur bond substituted nucleic acid aptamer fragment through a linking group. The phosphorothioate modified aptamer drug conjugate provided by the invention not only has all the advantages of an aptamer, but also greatly improves the enzyme digestion resistance of the aptamer-mitomycin C conjugate and prolongs the blood circulation half-life period by modifying phosphorothioate of a phosphate skeleton of an aptamer fragment; and in addition, the stability is improved, meanwhile, the original targeting property and specificity are reserved, and the high industrialization prospect is achieved.

The invention relates to a composition for preventing scar adhesion, a postoperative anti-adhesion material and application. Epidural scar adhesion is an important cause of postoperative lumbar surgery failure syndrome, and the invention aims to provide a drug-loaded postoperative sealing material which can seal wounds and realize stable release of drugs at the same time. The invention firstly provides the mitomycin C-IFN gamma-sodium hyaluronate conjugate for preventing scar adhesion, the conjugate can effectively inhibit scar tissue formation and slow down the drug degradation speed, and when the conjugate is applied to a polyethylene glycol sealant, the sealing effects of low swelling and rapid condensation can be achieved. The product is especially suitable for spinal surgeries such as laminectomy and the like, and has good clinical application value.

The invention relates to the technical field of drug inhibitors, in particular to a novel PD-1 tumor immunosuppressant and a drug preparation method thereof. The immunosuppressant is prepared from byweight, 30-45 parts of PD-1 monoclonal antibody, 2-6 parts of alkaloid, 4-7 parts of antibiotic, 3-9 parts of alkylating agent, 1-5 parts of platinum agent and 5-9 parts of metabolic antagonist; the alkaloid consists of one or more of paclitaxel, vincristine and docetaxel; the antibiotic consists of one or more of epirubicin, idarubicin and mitomycin; the alkylating agent is one or two of ifosfamide and dacarbazine; the platinum agent is one or two of cisplatin and oxaliplatin; the metabolic antagonist is one or more of gemcitabine, cytarabine and tegafur. The immunosuppressant can block the interaction between PD-L1 molecules expressed on tumor cells and receptors on activated T cells, inhibit the apoptosis of the activated T cells and improve the killing capability of the tumor cells.

Disclosed is a slow release injection agent of anticancer composition containing nitrosourea drugs and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the nitrosourea drugs are selected from Carmustine, Nimustine or Fotemustine, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or temozolomide and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent, for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.

The invention provides a treatment method for the de-proliferation ability of feeder cells for NK cell culture, and uses mitomycin C to process the feeder cells. The de-proliferation operation methodof the feeder cells provided by the invention has low costs, and is simple to operate and convenient to promote and use; the cell morphology of the feeder cells processed by the method remains intact,the expansion of NK cells can be better stimulated, so that the prepared NK cells have very high purity and killing activity, through detection, when the cells are cultured for 14 days, the purity ofthe NK cells reaches 94% or more, and the amplification multiple reaches 720 or more; when the effector-target ratio is 5:1, the killing activity of the NK cells on K562 cells is 60% or more; and thefeeder cells treated by the method are almost all killed by the NK cells on the fourth day of culture without post-residue residues, and the method can be applied and promoted in clinical research.

The invention discloses a YAP1 gene and application of an inhibitor in enhancing chemosensitivity of a stem cell of bladder cancer. The YAP1 gene is related to chemosensitivity of the stem cell of bladder cancer. The inhibitor where the YAP1 gene is highly expressed can improve the chemosensitivity of the stem cell of bladder cancer on chemotherapeutics mitomycin C and cis-platinum by down-regulating the expression of the YAP1 gene, so that the inhibiting rate of the chemotherapeutics mitomycin C and cis-platinum on the stem cell of bladder cancer is increased. The inhibitor where the YAP1 gene is highly expressed can be any one or more of siRNA, shRNA, dsRNA, miRNA, cDNA, a small molecular compound, a peptide and an antibody, wherein the small molecular compound is a 2-amido benzoxazole derivative.

The invention provides an anti-cancer composition. The anti-cancer composition comprises cisplatin and transplatin. The invention further provides a use method and application range of the anti-cancercomposition. According to the invention, the safety of combined application of the cisplatin and the transplatin to the interiors of animal bodies, the effectiveness of killing sensitive tumor cellsand the use method are comprehensively researched in detail. Under the conventional induction condition of drug resistance, the probability that the sensitive cells generate drug resistance is very low. In a parallel contrast experiment under the same condition, the probability that the cisplatin generates drug resistance is 87%, mitomycin-C and olaparib induce the drug resistance with high probabilities of higher than 90%, and the probability that the drug resistance is generated by the anti-cancer composition is 22%.

The invention discloses a method for establishing a transgenic removable human skin fibroblast feeder cell line. By utilizing a retrovirus-mediated gene transfer way, the production tool introduces areinforced green fluorescent protein gene, a telomerase reverse transcriptase gene and a herpes simplex virus thymidine kinase gene into human skin fibroblasts to establish a fluorescence-labeled immortalization-removable TERT + TK-D human feeder cell line. After being treated by mitomycin C, the established cell line serving as feeder cells is co-cultured with human limbal stem cells, and the culture result is compared with a culture result of 3T3 feeder cells. Transgenic fluorescence-labeled immortalization-removable human skin fibroblast feeder cells are expected to replace the 3T3 cells for corneal regeneration therapy.

The invention discloses a method for screening and identifying stress response gene expression regulatory factors. The invention develops a method for enriching protein binding genome DNA fragments toconstruct a luciferase report library for identifying clones capable of responding to environmental stress. E.coil is used as a model system for preparing a cell lysis solution and the genome DNA fragments; the cell lysis solution is mixed with the genome DNA fragments, the protein-bound DNA fragments are enriched, are separated from non-bound DNA fragments by using a membrane rotating column andare used for making the luciferase report library, and after DH5[alpha] is transformed, resistant clones are screened on an Amp antibiotic board; mitomycin C or arsenite is used for treatment, more than two times of clones induced by luciferase are identified, and correlation is proved by further analysis; and therefore, the screening and identifying method is efficient and accurate.

The invention relates to the technical field of biological medicines, in particular to application of mitomycin C in preparation of antidepressant drugs. The invention provides application of mitomycin C in preparation of antidepressant drugs. The mitomycin C can effectively inhibit the increase of PC12 cell inflammation level caused by corticosterone induction and relieve inflammatory response, thereby playing an anti-depression effect. The corticosterone-induced depression model can simulate the pathological process of depression, and can be used for efficacy evaluation and mechanism exploration of antidepressant drugs. The traditional Chinese medicine composition can provide scientific basis for clinical medication of depression.

The invention relates to a drug combination, namely, a slow-release injection, carrying nimustine and a synergistic agent thereof at the same time, which consists of slow-release accessories and active anti-cancer ingredients. The active anti-cancer ingredients comprise the nimustine and the synergistic agent thereof (vinorelbine, melphalan or mitomycin C) respectively. The viscosity of the slow-release injection is 10cp to 650cp (at the temperature of 20 DEG C to 30 DEG C). The active anti-cancer ingredients can also be prepared into a slow-release implant. The slow-release accessories are mainly biological soluble and degradable macromolecular polymerizers that can be absorbed. During the process of degradation and adsorption, the macromolecular polymerizers can slowly release the active anti-cancer ingredients to parts of tumors, thus obviously reducing the toxic reaction of the whole body as well as maintaining the concentration of effective drugs at the parts of the tumors. Putting the anti-cancer drug combination at the parts of the tumors can not only reduce the toxic reaction of the whole body active against cancer, but also selectively raise the drug concentration of the parts of the tumors and enhance the curative effect of nonspecific treatment, such as chemotherapy drugs and radiotherapy treatment, and the like. Solid tumors include glioma, osteoma sarcomatosum, lymphoma, lung cancer, intestinal cancer, oophoroma, and the like.